Skip to main content
. Author manuscript; available in PMC: 2019 Mar 14.
Published in final edited form as: Infect Control Hosp Epidemiol. 2017 Mar 8;38(6):663–669. doi: 10.1017/ice.2017.34

FIGURE 2.

FIGURE 2.

Prevalence-specific multidrug-resistant organism (MDRO) acquisition rates as a function of microbiome effect and antibiotic usage levels. Acquisition rates for high- and low-prevalence MDROs grow exponentially with increasing microbiome effect, and statistically significant benefits of decreased antibiotic usage are observed at microbiome effect levels of ~ 1.2 and higher.